MX2020011367A - Compuesto oxo-sustituido. - Google Patents
Compuesto oxo-sustituido.Info
- Publication number
- MX2020011367A MX2020011367A MX2020011367A MX2020011367A MX2020011367A MX 2020011367 A MX2020011367 A MX 2020011367A MX 2020011367 A MX2020011367 A MX 2020011367A MX 2020011367 A MX2020011367 A MX 2020011367A MX 2020011367 A MX2020011367 A MX 2020011367A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- preventive
- oxo
- inhibitory effect
- lactamase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018087761 | 2018-04-27 | ||
| PCT/JP2019/018011 WO2019208797A1 (ja) | 2018-04-27 | 2019-04-26 | オキソ置換化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011367A true MX2020011367A (es) | 2021-02-09 |
Family
ID=68295570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011367A MX2020011367A (es) | 2018-04-27 | 2019-04-26 | Compuesto oxo-sustituido. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11702431B2 (https=) |
| EP (1) | EP3786168A4 (https=) |
| JP (2) | JP7360132B2 (https=) |
| KR (1) | KR102679411B1 (https=) |
| CN (2) | CN112135830B (https=) |
| AU (1) | AU2019259818B2 (https=) |
| CA (1) | CA3098433A1 (https=) |
| EA (1) | EA202092579A1 (https=) |
| IL (1) | IL278262B2 (https=) |
| MX (1) | MX2020011367A (https=) |
| PH (1) | PH12020551772A1 (https=) |
| SG (1) | SG11202010661SA (https=) |
| TW (1) | TWI829686B (https=) |
| UA (1) | UA129150C2 (https=) |
| WO (1) | WO2019208797A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2020138499A1 (ja) * | 2018-12-28 | 2021-11-04 | 大日本住友製薬株式会社 | アルキル置換化合物 |
| EP4049680A4 (en) * | 2019-10-25 | 2024-01-10 | Sumitomo Pharma Co., Ltd. | NEW SUBSTITUTED CONDENSED RING CONNECTION |
| US11476003B2 (en) * | 2020-12-15 | 2022-10-18 | Biodesix, Inc. | Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings |
| WO2024128238A1 (ja) | 2022-12-13 | 2024-06-20 | 住友ファーマ株式会社 | 細菌感染症の治療剤 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2705393A1 (en) | 2007-11-13 | 2009-05-22 | Protez Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| AU2013355110B2 (en) | 2012-12-07 | 2017-11-09 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| MX2015008627A (es) | 2013-01-04 | 2015-09-23 | Rempex Pharmaceuticals Inc | Derivados de acido boronico y usos terapeuticos de los mismos. |
| KR20150103269A (ko) | 2013-01-04 | 2015-09-09 | 렘펙스 파머수티클스 인코퍼레이티드 | 보론산 유도체 및 그의 치료적 용도 |
| EP2943204B1 (en) | 2013-01-10 | 2019-03-13 | Venatorx Pharmaceuticals Inc | Beta-lactamase inhibitors |
| EP2970340B1 (en) | 2013-03-14 | 2020-02-12 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| AU2015264418A1 (en) | 2014-05-19 | 2016-11-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| WO2015191907A1 (en) | 2014-06-11 | 2015-12-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2016003929A1 (en) | 2014-07-01 | 2016-01-07 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US20180051041A1 (en) | 2015-03-17 | 2018-02-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| WO2017044828A1 (en) | 2015-09-11 | 2017-03-16 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
-
2019
- 2019-04-26 KR KR1020207033733A patent/KR102679411B1/ko active Active
- 2019-04-26 CA CA3098433A patent/CA3098433A1/en active Pending
- 2019-04-26 TW TW108114791A patent/TWI829686B/zh active
- 2019-04-26 CN CN201980028757.2A patent/CN112135830B/zh active Active
- 2019-04-26 US US17/050,747 patent/US11702431B2/en active Active
- 2019-04-26 EP EP19793135.5A patent/EP3786168A4/en active Pending
- 2019-04-26 IL IL278262A patent/IL278262B2/en unknown
- 2019-04-26 CN CN202410723545.9A patent/CN118638140A/zh active Pending
- 2019-04-26 MX MX2020011367A patent/MX2020011367A/es unknown
- 2019-04-26 AU AU2019259818A patent/AU2019259818B2/en active Active
- 2019-04-26 JP JP2020515615A patent/JP7360132B2/ja active Active
- 2019-04-26 EA EA202092579A patent/EA202092579A1/ru unknown
- 2019-04-26 UA UAA202007528A patent/UA129150C2/uk unknown
- 2019-04-26 SG SG11202010661SA patent/SG11202010661SA/en unknown
- 2019-04-26 WO PCT/JP2019/018011 patent/WO2019208797A1/ja not_active Ceased
-
2020
- 2020-10-26 PH PH12020551772A patent/PH12020551772A1/en unknown
- 2020-12-29 US US17/136,806 patent/US11066425B1/en active Active
-
2023
- 2023-04-28 US US18/309,641 patent/US20230287009A1/en active Pending
- 2023-09-21 JP JP2023156567A patent/JP7598594B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210147448A1 (en) | 2021-05-20 |
| PH12020551772A1 (en) | 2021-07-12 |
| TW201945006A (zh) | 2019-12-01 |
| KR102679411B1 (ko) | 2024-07-01 |
| TWI829686B (zh) | 2024-01-21 |
| IL278262B1 (en) | 2024-12-01 |
| KR20210005910A (ko) | 2021-01-15 |
| IL278262B2 (en) | 2025-04-01 |
| JPWO2019208797A1 (ja) | 2021-05-27 |
| EP3786168A1 (en) | 2021-03-03 |
| TW202421162A (zh) | 2024-06-01 |
| US20230287009A1 (en) | 2023-09-14 |
| AU2019259818A1 (en) | 2020-11-26 |
| IL278262A (en) | 2020-12-31 |
| JP7360132B2 (ja) | 2023-10-12 |
| EA202092579A1 (ru) | 2021-04-01 |
| JP2023168413A (ja) | 2023-11-24 |
| SG11202010661SA (en) | 2020-11-27 |
| AU2019259818B2 (en) | 2023-06-01 |
| CA3098433A1 (en) | 2019-10-31 |
| CN112135830A (zh) | 2020-12-25 |
| US11702431B2 (en) | 2023-07-18 |
| BR112020021631A8 (pt) | 2023-02-28 |
| US11066425B1 (en) | 2021-07-20 |
| BR112020021631A2 (pt) | 2021-01-26 |
| JP7598594B2 (ja) | 2024-12-12 |
| CN112135830B (zh) | 2024-06-14 |
| EP3786168A4 (en) | 2022-03-23 |
| WO2019208797A1 (ja) | 2019-10-31 |
| CN118638140A (zh) | 2024-09-13 |
| UA129150C2 (uk) | 2025-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| CO2019002556A2 (es) | Composición farmacéutica | |
| CO2022008968A2 (es) | Nuevos derivados de metilquinazolinona | |
| MX2020011367A (es) | Compuesto oxo-sustituido. | |
| AR112271A1 (es) | Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales | |
| DOP2025000244A (es) | Compuestos y métodos para el tratamiento de infecciones virales | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| MX2023002233A (es) | Compuestos fosfolipidos y usos de estos. | |
| MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
| MX2024009926A (es) | Composiciones y metodos para tratar trastornos del snc. | |
| DOP2022000076A (es) | Inhibidores del factor d del complemento para administración oral | |
| CL2022001353A1 (es) | Inhibidores de egfr | |
| AR121598A1 (es) | Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano | |
| ECSP23080267A (es) | Compuestos de lactivicina, su preparación y uso como agentes antibacterianos | |
| AR132764A1 (es) | Inhibidores de tyk2 y sus usos | |
| PH12022550983A1 (en) | Novel substituted condensed ring compound | |
| AR118141A1 (es) | Compuestos para el tratamiento, alivio o prevención de trastornos asociados con los agregados de tau | |
| MX2024010671A (es) | Compuestos antivirales y metodos de elaboracion y uso de los mismos. | |
| AR131842A1 (es) | Métodos para tratar gliomas | |
| AR126393A1 (es) | Terapia combinada para el tratamiento de enfermedades hepáticas | |
| AR083780A1 (es) | Composicion farmaceutica para tratar infecciones del hcv | |
| MX2022000729A (es) | Terapia de combinacion para el tratamiento del cancer. | |
| AR131708A1 (es) | Protacts degradantes de kras a base de cereblon y usos relacionados con los mismos | |
| AR134205A1 (es) | Inhibidores de ripk1 y métodos de uso | |
| CL2025001435A1 (es) | Compuestos inhibidores de ddr1 para tratar cáncer. |